Why Novavax Beat the Market on Monday

Novavax (NASDAQ: NVAX), best known these days for the NVX-CoV2373 coronavirus vaccine it's developed, saw its shares rise by 1.5% on Monday, against a stock market that essentially traded sideways. Investors seemed to be cautiously optimistic about the company's latest news on the regulatory front.

Novavax announced that it has formally submitted a biologics license application (BLA) for NVX-CoV2373 to South Korea's Ministry of Food and Drug Safety. It has done so in collaboration with South Korean biotech SK bioscience.

Image source: Getty Images.

Continue reading

Source Fool.com